calaspargase pegol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
enzymes 5321 941577-06-6

Description:

MoleculeDescription

Synonyms:

  • calaspargase pegol
  • asparlas
  • EZN-2285
L-asparaginase is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of ASPARLAS is thought to be based on selective killing of leukemic cells due to depletion of plasma L-asparagine. Leukemic cells with low expression of asparagine synthetase have a reduced ability to synthesize L-asparagine, and therefore depend on an exogenous source of L-asparagine for survival.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 2018 FDA SERVIER PHARMA LLC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypertriglyceridaemia 87.06 66.28 19 482 16135 110572663
Treatment delayed 73.89 66.28 10 491 497 110588301
Infusion related reaction 73.18 66.28 35 466 381127 110207671

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XX86 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
FDA CS M0001815 Asparaginase
FDA EPC N0000175669 Asparagine-specific Enzyme
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01XX Other antineoplastic agents 33 drugs
adagrasibafliberceptaltretamineamsacrineanagrelidearsenic trioxideasparaginasebelzutifancelecoxibdarinaparsindenileukin diftitoxeflornithine show all 33 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute lymphoblastic leukemia indication 413440007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
T9FVH03HMZ UNII
C2699709 UMLSCUI
CHEBI:753666 CHEBI
CHEMBL2108728 ChEMBL_ID
DB14730 DRUGBANK_ID
D10096 KEGG_DRUG
9250 INN_ID
C000595188 MESH_SUPPLEMENTAL_RECORD_UI
783683008 SNOMEDCT_US
783687009 SNOMEDCT_US
303899 MMSL
35900 MMSL
d09115 MMSL
2121416 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
asparlas HUMAN PRESCRIPTION DRUG LABEL 1 72694-515 INJECTION, SOLUTION 750 U INTRAVENOUS BLA 28 sections